Status of Clinical Trials Evaluating Eicosanoids in Atherosclerotic Vascular Disease and Thrombosis

  • Laurence A. Harker
Part of the GWUMC Department of Biochemistry Annual Spring Symposia book series (GWUN)


The indications for the use of agents that modify eicosanoid metabolism in the management of patients with arterial vascular disease are limited despite extensive basic, experimental animal and clinical studies. Aspirin is clearly beneficial in men with transient ischemic attacks and patients with unstable angina. It is also anti-thrombotic when used in combination with oral anticoagulants in patients with artificial heart valves and in patients with arteriovenous cannulas undergoing he-modialysis (and manifest associated underlying platelet dysfunction). In general, the negative clinical trials have been uninformative because of uncertainty with respect to the role of eicosanoids in the pathogenesis of the outcome events, inadequately defined mechanisms of drug actions, and uncertainty regarding the effective doses for the drugs in the trials. In the absence of established mechanisms of drug action, dose regimens appear to require objective assays with thrombotic endpoints rather than the use of in vitro biochemical measurements of less certain interpretation.


Transient Ischemic Attack Coronary Artery Spasm Graft Occlusion Artificial Heart Valve Saphenous Vein Bypass 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anturane Reinfarction Italian Study, 1982, Sulfinpyrazone in post-myocardial infarction, Lancet 1:237–242.Google Scholar
  2. Anturane Reinfarction Trial Policy Committee, 1982, The Anturane Reinfarction Trial: Reevaluation of outcome, N. Engl. J. Med. 306:1005–1008.CrossRefGoogle Scholar
  3. Anturane Reinfarction Trial Research Group, 1980, Sulfinpyrazone in the prevention of sudden death after myocardial infarction, N. Engl. J. Med. 302:250–256.CrossRefGoogle Scholar
  4. Aspirin Myocardial Infarction Study Research Group, 1980, A randomized, controlled trial of aspirin in persons recovered from myocardial infarction, JA.M.A. 243:661–669.CrossRefGoogle Scholar
  5. Breddin, K., Loew, D., Lechner, K., Uberla, K., and Walter, E., 1980, Secondary prevention of myocardial infarction. Comparison of acetyl-salicylic acid, phenprocoumon and placebo. Hae-mostasis 9:325–344.Google Scholar
  6. Canadian Cooperative Study Group, 1978, A randomized trial of aspirin and sulfinpyrazone in threatened stroke, N. Engl. J. Med. 299:53–59.CrossRefGoogle Scholar
  7. Chesebro, J.H., Clements, I.P., Fuster, V., Elveback, L.R., Smith, H.C, Bordsley, W.T., Frey, R.L., Holmes, D.R., Vlietstra, R.E., Pluth, J.R., Wallace, R.B., Puga, F.J., Orszulak, T.A., Piehler, J.M., Schaff, H.V., and Danielson, G.K., 1982, A platelet-inhibitor drug trial in coronary artery bypass operations. Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency, N. Engl. J. Med. 307:73–78.PubMedCrossRefGoogle Scholar
  8. Chesebro, J.H., Fuster, V., Elveback, L.R., Clements, I.P., Smith, H.C, Holmes, D.R., Bardsley, W.T., Pluth, J.R., Wallace, R.B., Puga, F.J., Orszulak, T.A., Piehler, J.M., Danielson, G.K., Schaff, H.V., and Frye, R.L., 1984, Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations, N. Engl. J. Med. 310:209–214.PubMedCrossRefGoogle Scholar
  9. Coronary Drug Project Research Group, 1976, Aspirin in coronary heart disease, J. Chronic Dis. 29:625–642.CrossRefGoogle Scholar
  10. Dale, J., 1976, Arterial thromboembolic complications in patients with Staff-Edwards aortic ball valve prostheses, Am. Heart J. 91:653–659.PubMedCrossRefGoogle Scholar
  11. Del Zoppo, G.J., and Harker, L.A., 1984, Blood/vessel interaction in coronary disease, Hosp. Pract. 19:163–182.Google Scholar
  12. DeWood, M.A., Spores, J., Notske, R., Mouser, L.T., Burroughs, R., Golden, M.S., and Lang, H.T., 1980, Prevalence of coronary occlusion during the early hours of transmural myocardial infarction, N. Engl. J. Med. 303:897–902.PubMedCrossRefGoogle Scholar
  13. Elwood, P.C, Cochrane, A.L., Burr, M.L., Sweetnam, P.M., Williams, G., Welsby, E., Hughes, S.J., and Renton, R., 1974, A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction, Br. Med. J. 1:436–440.PubMedCrossRefGoogle Scholar
  14. Elwood, P.C., and Sweetnam, P.M., 1979, Aspirin and secondary mortality after myocardial infarction, Lancet 2:1313–1315.PubMedCrossRefGoogle Scholar
  15. Fields, W.S., 1977, Controlled trial of aspirin in cerebral ischemia, Stroke 8:308.CrossRefGoogle Scholar
  16. Harlan, J. M., and Harker, L. A., 1983, Thrombosis and coronary artery disease, in: Current Concepts, Upjohn, Kalamazoo, ML, pp. 1–56.Google Scholar
  17. Harter, H.R., Burch, J.W., Majerus, P.W., Stanford, N., Delmez, J.A., Anderson, C.B., and Weerts, C.A., 1979, Prevention of thrombosis in patients on hemodialysis by low-dose aspirin, N. Engl. J. Med. 301:577–579.PubMedCrossRefGoogle Scholar
  18. Lewis, H.D., Davis, J.W., Archibald, D.G., Steinke, W.E., Smitherman, T.C, Doherty, J.E., Schnaper, H.W., LeWinter, M.M., Linares, E., Pouget, J.M., Sabharwal, S.C, Chesler, E., and DeMots, H., 1983, Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina, N. Engl. J. Med. 309:396–403.PubMedCrossRefGoogle Scholar
  19. Lewis, P., and Taylor, H. M., 1983, Dazoxiben—clinical prospects for a thromboxane synthetase inhibitor, Br. J. Clin. Pharmacol. 15:1S–140S.Google Scholar
  20. Maseri, A., L’Abbate, A., Baroldi, G., Chierchia, S., Marzilli, M., Ballestra, A.M., Severi, S., Parodi, O., Biagini, A., Distante, A., and Pesola, A., 1978, Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of “preinfarction” angina, N. Engl. J. Med. 299:1271–1277.PubMedCrossRefGoogle Scholar
  21. Persantine-Aspirin Reinfarction Study Research Group, 1980, Persantine and aspirin in coronary heart disease, Circulation 62:449–461.CrossRefGoogle Scholar
  22. Rentrop, K.P., Blanke, H., Karsch, K.R., Kaiser, H., Kostering, H., and Leitz, K., 1981, Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris, Circulation 63:307–317.PubMedCrossRefGoogle Scholar
  23. Robertson, R.M, Robertson, D., Roberts, L.J., Maas, R.L., FitzGerald, G.A., Friesinger, G.C, and Oates, J.A., 1981, Thromboxane A2 in vasotonic angina pectoris: Evidence from direct measurements and inhibitor trials, N. Engl. J. Med. 304:998–1003.PubMedCrossRefGoogle Scholar
  24. Temple, R., and Pledger, G.W., 1982, The FDA’s critique of the Anturane Reinfarction Trial, N. Engl. J. Med. 303:1488–1492.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Laurence A. Harker
    • 1
  1. 1.Roon Research Center for Arteriosclerosis and ThrombosisScripps Clinic and Research FoundationLa JollaUSA

Personalised recommendations